Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

Published:2011-12 Issue:12 Volume:10 Page:1049-1057
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

de Yebenes Justo Garcia,Landwehrmeyer Bernhard,Squitieri Ferdinando,Reilmann Ralf,Rosser Anne,Barker Roger A,Saft Carsten,Magnet Markus K,Sword Alastair,Rembratt Åsa,Tedroff Joakim

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference32 articles.

1. Huntington's disease;Walker;Lancet,2007

2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes;Cell,1993

3. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity;Rosas;Brain,2008

4. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease;Heinsen;Acta Neuropathol,1999

5. Thalamic metabolism and symptom onset in preclinical Huntington's disease;Feigin;Brain,2007

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease;Archives of Pharmacal Research;2024-05-19

2. Latest advances on new promising molecular-based therapeutic approaches for Huntington’s disease;Journal of Translational Internal Medicine;2024-04-01

3. Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies;International Journal of Molecular Sciences;2024-03-29

4. Design and synthesis of fused azacyclic and azaspirocyclic γ-lactams targeting dopaminergic D2/D4 receptors;Journal of Molecular Structure;2024-03

5. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study;The Lancet Neurology;2024-03